Barr ANDAs
Executive Summary
Barr ANDAs: The company met with FDA on Sept. 7 to discuss delays in approvals for five ANDAs. Barr said it has received approval on the biostudies of some of the ANDAs; however, final approval has been stalled at the agency. FDA blamed the delay on a general slowdown in approvals due to the generics investigation. However, according to the company, one ANDA had been delayed six weeks because the FDA employee assigned to the application refused to review a Barr ANDA. Among the ANDAs discussed at the meeting were conjugated estrogens and an erythromycin formulation. Barr submitted blood level studies for the conjugated estrogens in accordance with an FDA decision on bioequivalence requirements for generic forms of Ayerst's Premarin. Reportedly, FDA has asked Barr to submit new biostudies for the erythromycin ANDA. Barr has applications pending for two lower strengths of its erythromycin 500 mg enteric coated tabs approved in November 1988.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.